Shots:

• The company temporarily paused enrollment in the P-III (IMPOWER 22 & 24) clinical studies to evaluate islatravir (qm, PO) vs FTC/TDF for pre-exposure prophylaxis in patients at high risk of HIV-1 infection
• Following the recommendation of PrEP eDMC, the company implements additional monitoring measures for study participants, including increasing the frequency of total lymphocyte and CD4+ T-cell assessments
• The company is conducting further analyses for other ongoing studies while enrolled patients in the P-III trials will continue to receive the study medicine. Islatravir (MK-8591) is an NRTTIs inhibitor that is designed to prevent HIV-1

Ref: Businesswire | Image: Merck